Key result
IL-10-Ig gene therapy reduced the myocarditis area compared to control plasmid in rats with experimental autoimmune myocarditis.
Why the study?
Does IL-10-Ig gene transfer reduce myocarditis severity and IL-17 expression in a rat model of experimental autoimmune myocarditis?
Does IL-10-Ig gene transfer reduce myocarditis severity and IL-17 expression in a rat model of experimental autoimmune myocarditis?
IL-10-Ig gene transfer ameliorates experimental autoimmune myocarditis in rats, likely by inhibiting the highly expressed pro-inflammatory cytokine IL-17.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for IL-10-Ig gene therapy in myocarditis; prospective trials needed before clinical consideration.
BACKGROUND: T-helper (Th)1/Th2 cytokine balance plays an important role in the pathogenesis of myocarditis. Recently, some studies indicate that interleukin (IL)-17, known as a T cell (Th17)-derived proinflammatory cytokine, is the major mediator of tissue inflammation in inflammatory and autoimmune diseases. Experimental autoimmune myocarditis (EAM) is a T cell-mediated autoimmune disease; however, the pathogenic role of IL-17 in the development of rat EAM remains largely unknown. METHODS AND RESULTS: In the present study, alterations of IL-17-related protein expressions were investigated and then the effect of hydrodynamic-based delivery of plasmid DNA encoding the IL-10-Ig gene on rat EAM and the effect of IL-10-Ig on IL-17 was evaluated. The results showed that IL-17 was expressed more highly than IFN-gamma expressed by Th1 cells in alphabetaT cells and the peaks of IL-17 related protein expression in the heart were the early phase of EAM. Moreover, we observed that IL-10-Ig gene therapy was effective in controlling EAM and that IL-10-Ig significantly suppressed the expression of IL-17 as well as other proinflammatory cytokines, IL-1beta and TNF-alpha, in IL-1-stimulated splenocytes cultured from EAM rats. CONCLUSIONS: IL-17 is highly produced by alphabetaT cells in the early phase of EAM hearts and IL-17 inhibition might be a possible mechanism of the amelioration of EAM by IL-10-Ig treatment. These data suggest that IL-17 produced by Th17 plays an important role in the pathogenesis of rat EAM.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2008) studied Experimental autoimmune myocarditis (n=24). IL-10-Ig gene transfer vs. SP-Ig gene transfer (control plasmid) was evaluated on Myocarditis area (%) (p=0.0001). IL-10-Ig gene therapy reduced the myocarditis area compared to control plasmid in rats with experimental autoimmune myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: